← Back to patent-cliff list
CAS 1344087-70-2
(4aR,4bS,6aS,7R,9aS,9bR)-7-hydroxy-4a,6a,7-trimethyl-1,3,4,4a,4b,5,6,6a,7,8,9,9a,9b,10-tetradecahydro-2H-indeno[5,4-f]quinolin-2-one
Codes: DUTA-029
Application context (from source-drug indications)
Benign prostatic hyperplasiaDutasteride/Tamsulosin HydrochlorideUrinary retentionDutasterideBenign prostatic hyperplasiaDutasterideAlopeciaDutasterideAlcohol abuseDutasterideBladder cancerDutasterideProstate cancerDutasteride
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Dutasteride/Tamsulosin Hydrochloride | Tier C — Watch / trade | - |
| Dutasteride | Tier B — Position early | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
(8R,9S,10R,13S,14S)-10,13-dimethyl-1,6,7,8,9,10,11,12,13,14,15,16-dodecahydro-3H-cyclopenta[a]phenanthrene-3,17(2H)-dione→3-((3aS,5aS,6R,9aR,9bS)-3a,6-dimethyl-3,7-dioxododecahydro-1H-cyclopenta[a]naphthalen-6-yl)propanoic acid→(4aR,4bS,6aS,9aS,9bR)-4a,6a-dimethyl-3,4,4a,4b,5,6,6a,8,9,9a,9b,10-dodecahydro-1H-indeno[5,4-f]quinoline-2,7-dione→(4aR,4bS,6aS,7R,9aS,9bR)-7-hydroxy-4a,6a,7-trimethyl-1,3,4,4a,4b,5,6,6a,7,8,9,9a,9b,10-tetradecahydro-2H-indeno[5,4-f]quinolin-2-one→(4aR,4bS,6aS,9aS,9bS)-4a,6a,7-trimethyl-1,3,4,4a,4b,5,6,6a,9,9a,9b,10-dodecahydro-2H-indeno[5,4-f]quinolin-2-one→(4aR,4bS,6aR,7S,9aS,9bS,11aR)-4a,6a,7-trimethylhexadecahydro-2H-indeno[5,4-f]quinolin-2-one→(4aR,4bS,6aS,7S,9aS,9bS,11aR)-4a,6a-dimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxylic acid→(4aR,4bS,6aS,7S,9aS,9bS,11aR)-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxylic acid→2,5-bis(trifluoromethyl)aniline
(8R,9S,10R,13S,14S)-10,13-dimethyl-1,6,7,8,9,10,11,12,13,14,15,16-dodecahydro-3H-cyclopenta[a]phenanthrene-3,17(2H)-dione→3-((3aS,5aS,6R,9aR,9bS)-3a,6-dimethyl-3,7-dioxododecahydro-1H-cyclopenta[a]naphthalen-6-yl)propanoic acid→(4aR,4bS,6aS,9aS,9bR)-4a,6a-dimethyl-3,4,4a,4b,5,6,6a,8,9,9a,9b,10-dodecahydro-1H-indeno[5,4-f]quinoline-2,7-dione→(4aR,4bS,6aS,7R,9aS,9bR)-7-hydroxy-4a,6a,7-trimethyl-1,3,4,4a,4b,5,6,6a,7,8,9,9a,9b,10-tetradecahydro-2H-indeno[5,4-f]quinolin-2-one→(4aR,4bS,6aS,9aS,9bS)-4a,6a,7-trimethyl-1,3,4,4a,4b,5,6,6a,9,9a,9b,10-dodecahydro-2H-indeno[5,4-f]quinolin-2-one→(4aR,4bS,6aR,7S,9aS,9bS,11aR)-4a,6a,7-trimethylhexadecahydro-2H-indeno[5,4-f]quinolin-2-one→(4aR,4bS,6aS,7S,9aS,9bS,11aR)-4a,6a-dimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxylic acid→(4aR,4bS,6aS,7S,9aS,9bS,11aR)-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxylic acid→2,5-bis(trifluoromethyl)aniline
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.